Logo

CURX

Curanex Pharmaceuticals Inc Common Stock

CURX

Curanex Pharmaceuticals Inc Common Stock • NASDAQ
$0.49 ▲ 5.25% (+0.02)
Market Cap $13.26 M
52w High $9.18
52w Low $0.38
Dividend Yield 0%
P/E -24.36
Volume 47.45K
Outstanding Shares 27.22M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $951.327K ▲ $-954.059K ▼ 0% $-0.04 ▼ $-934.53K ▼
Q2-2025 $0 $57.658K ▼ $-60.346K ▲ 0% $-0.002 ▲ $-42.225K ▲
Q1-2025 $0 $137.452K ▼ $-137.583K ▼ 0% $-0.005 ▼ $-121.594K ▼
Q4-2024 $0 $138.591K ▲ $-137.163K ▼ 0% $0 $-63.915K ▲
Q3-2024 $0 $102.07K $-99.942K 0% $0 $-102.07K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $5.831M ▲ $14.478M ▲ $185.955K ▼ $14.292M ▲
Q2-2025 $108.862K ▼ $787.174K ▲ $481.743K ▲ $305.431K ▼
Q1-2025 $198.943K ▲ $786.94K ▲ $421.163K ▲ $365.777K ▼
Q4-2024 $148.891K ▼ $517.935K ▼ $14.575K ▲ $503.36K ▼
Q3-2024 $244.32K $646.122K $5.599K $640.523K

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-954.059K ▼ $-9.187M ▼ $0 $14.909M ▲ $5.722M ▲ $-9.187M ▼
Q2-2025 $-60.346K ▲ $-290.081K ▼ $0 $200K $-90.081K ▼ $-290.081K ▼
Q1-2025 $-137.583K $-149.948K $0 $200K $50.052K $-149.948K

Five-Year Company Overview

Income Statement

Income Statement Curanex is essentially a pure research-stage biotech story right now. It has no product sales and no meaningful revenue, so its income statement is driven almost entirely by R&D and overhead costs. That means recurring net losses are expected for the foreseeable future as the company funds lab work, preclinical studies, and eventual clinical trials. Any small earnings-per-share movements so far mainly reflect accounting noise, not a change in the underlying business, because there is still no commercial product behind the numbers.

Balance Sheet

Balance Sheet The available data on the balance sheet is very limited, but the picture is typical for an early-stage biotech: the main assets are likely to be cash, intellectual property, and ongoing R&D projects, rather than factories or physical infrastructure. The company has no reported detail on debt, but its profile suggests it will rely heavily on issuing equity or partnering deals to fund development. That leaves investors exposed to future capital raises and potential dilution until the pipeline matures. Overall financial strength will depend on how much cash is on hand versus the pace of research spending, which is not fully disclosed here.

Cash Flow

Cash Flow There is no detailed cash-flow data provided, but the business model implies a straightforward pattern: cash flowing out for research, trials, salaries, and regulatory work, with no operating cash coming in from product sales. Cash burn and funding runway are therefore the key underlying issues, even if we cannot see the exact figures. In practice, that means the company will periodically need new financing rounds, licensing deals, or collaborations to keep development moving. Predictability is low because any partnership, grant, or equity raise could shift the cash picture quite quickly.

Competitive Edge

Competitive Edge Curanex occupies a specialized niche: botanical drugs for inflammatory and autoimmune diseases, trying to bridge traditional Chinese medicine with Western-style pharmaceutical standards. Its main potential strengths are a lead candidate built on decades of real-world use in traditional medicine, expertise in standardizing plant-based extracts, and a proprietary discovery and formulation platform. This creates a differentiated story versus classic small-molecule or biologic competitors. However, the company is still preclinical, with no approved products and no established market presence. It faces intense competition from large pharma and biotech firms already working in ulcerative colitis and other inflammatory conditions, plus the added complexity of a relatively uncommon regulatory path for botanical drugs. Its moat is promising but unproven, and time-to-market will likely be long.

Innovation and R&D

Innovation and R&D Innovation is the core of Curanex’s value. The lead candidate, Phyto-N, is a multi-component botanical extract aimed at calming overactive immune responses in conditions like ulcerative colitis, with exploratory work in several other inflammatory and metabolic diseases. The company’s R&D approach emphasizes standardizing plant-based therapies, turning a historically used traditional remedy into a modern, regulated drug candidate. A recent international patent filing suggests active work to secure intellectual property around a broad range of indications. That said, everything is still at the preclinical stage, so the scientific, regulatory, and clinical risks remain very high. Key future milestones, such as filing an application to begin human trials and generating early safety data, will be crucial tests of both the science and the development strategy.

Summary

Curanex is an early-stage, pre-revenue biotech focused on a single, differentiated idea: turning a traditional botanical remedy into a modern treatment for inflammatory diseases. Financially, it is in the classic development-phase pattern of no revenue, ongoing losses, and expected dependence on external funding. Strategically, its niche in botanical drugs, its standardization technology, and its intellectual property plans offer a distinctive angle but also expose it to a less familiar regulatory route with added uncertainty. The company’s future hinges heavily on the progress, safety, and efficacy of its lead program, Phyto-N. Until there is clear clinical data and better visibility on financing, the story remains high risk, high uncertainty, and tightly tied to one main asset and its ability to clear scientific and regulatory hurdles.

NEWS

October 22, 2025 · 7:00 AM UTC

Curanex Pharmaceuticals Inc. Engages Strategic Investor Relations to Enhance Investor Communications and Engagement

Read more

September 12, 2025 · 2:46 PM UTC

Curanex Pharmaceuticals Inc. Announces Exercise of the Over-Allotment Option by Underwriters

Read more